Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Boniface Echefu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Direct Comparison of Two Commonly Used Prenatal Valproate Doses Identifies Different Sex- and Age-Related Neurobehavioral Outcomes Across Development

    by Maria Becker, Denis Gorobets, Boniface Ezenwata Echefu, Akiva Juroviesky, Anna Beylis, Aviv Sela, Asher Ornoy

    Valproic acid (VPA) is a widely used anticonvulsant and mood stabilizer and a known teratogen associated with neural tube defects and neurodevelopmental disorders, including autism spectrum disorder (ASD). Prenatal VPA exposure is widely used to model ASD-like behaviors in rodents; however, direct comparisons between commonly used doses are lacking. We compared two widely used VPA doses (300 and 600 mg/kg) administered to pregnant mice on embryonic day 12.5 (E12.5). Male and female offspring were evaluated longitudinally for early neurological development, ultrasonic vocalizations, locomotor activity, anxiety-related behavior, sociability, and spontaneous alternation. Early development was largely preserved, although VPA300 delayed cliff aversion acquisition. Total ultrasonic vocalization production was unaffected, while selected call types were altered. Later behavioral effects differed across dose, sex, and age. In males, locomotor activity and center exploration were preserved, sociability was reduced by both VPA doses, and spontaneous alternation was reduced by VPA300 at postnatal day 70 (PND70). In females, locomotor activity was reduced by VPA600 at PND30 and VPA300 at PND70, center exploration was reduced by VPA600, and sociability was reduced by VPA300 at both ages and VPA600 at PND70. VPA600 was also associated with greater embryonic mortality. These findings show that the two VPA doses were associated with differing patterns of developmental and behavioral outcomes, without a consistent increase in severity at the higher dose.

  • Open Access

    S-Adenosylmethionine Depletion as Potential Rate-Limiting Nexus of Redox–Epigenetic Crosstalk in Neural Tube Defects: A Mechanistic Theory and Experimental Hypothesis

    by Boniface Ezenwata Echefu, Maria Becker, Asher Ornoy

    S-adenosylmethionine (SAMe) depletion may represent a rate-limiting nexus linking oxidative/nitrosative stress to epigenetic failure during neurulation. In this review, we synthesize evidence that diverse teratogenic and metabolic insults, including valproic acid (VPA) exposure, maternal diabetes, and folate-dependent one-carbon imbalance, converge on a shared redox–metabolic–epigenetic axis that lowers SAMe availability, elevates S-adenosylhomocysteine, weakens glutathione buffering, and disrupts DNA and histone methylation/demethylation programs of genes required for neural tube closure. This framework explains how redox stress can impair key developmental pathways such as Wnt/β-catenin, sonic hedgehog, and Pax3 while promoting neuroepithelial apoptosis, abnormal proliferation, and failure of morphogenetic coordination. By integrating redox stress with chromatin regulation and one-carbon metabolism, the proposed model provides a unifying mechanism for neural tube defect pathogenesis and positions SAMe-centered metabolic control as a plausible therapeutic target. Definitive testing will require demonstrating that redox stress lowers embryonic SAMe before closure failure, that this precedes epigenetic dysregulation at neurulation genes, and that restoring SAMe rescues neural tube development in vivo. Indeed, our recent experiments showed that SAMe prevented brain oxidative/nitrosative stress and neural tube defects (NTDs) induced by VPA in ICR mouse embryos. Although most studies alongside our hypothesis are experimental and the entire causal pathway in humans remains to be established, increased oxidative stress, reduced SAMe, and reduced SAMe:SAH ratio were also described in human NTDs.

  • Open Access

    Direct Comparison of Two Commonly Used Prenatal Valproate Doses Reveals Non-Linear and Sex-Dependent Neurobehavioral Outcomes Across Development

    by Maria Becker, Denis Gorobets, Boniface Echefu, Akiva Juroviesky, Anna Beylis, Aviv Sela, Asher Ornoy

    Valproic acid (VPA) is a widely used anticonvulsant and mood stabilizer and a known teratogen associated with neural tube defects and neurodevelopmental disorders, including autism spectrum disorder (ASD). Prenatal VPA exposure is widely used to model ASD-like behaviors in rodents; however, most studies employ a single dose, and direct comparisons between commonly used regimens are lacking. We therefore compared two widely used VPA doses (300 and 600 mg/kg) administered to pregnant mice on embryonic day 12.5 (E12.5). Male and female offspring were evaluated longitudinally for early neurological development, ultrasonic vocalizations, locomotor activity, anxiety-like behavior, sociability, and working memory. Prenatal VPA exposure produced non-linear, dose- and sex-dependent effects. Early neurodevelopment was largely preserved, with only mild and transient delays that were most evident after 300 mg/kg. In contrast, later behavioral alterations differed according to dose, sex, age, and behavioral measure. Sociability deficits were stable across doses in males but became more pronounced with age in females, whereas working memory impairment predominated after 600 mg/kg during adolescence and after 300 mg/kg in adulthood. These findings demonstrate that increasing prenatal VPA dose does not simply increase behavioral severity but produces distinct neurodevelopmental trajectories that depend on dose, sex, and developmental stage.

  • Open Access

    Prenatal Origin of Childhood Overweight, Obesity and Insulin Resistance, with Special Emphasis on Maternal Diabetes, Excessive Weight, Nutrition and Hormone Imbalances

    by Asher Ornoy, Boniface Echefu, Maria Becker

    Overweight in childhood, adolescence and adulthood is now a world-wide epidemic. A variety of preventive and therapeutic measures are being developed with partial success. Since the pioneering studies of D.J. Barker linking maternal famine in pregnancy to long—term undesirable effects on the offspring—the “metabolic syndrome” that stems from long-lasting epigenetic changes, it became evident that there are many undesirable events which affect in-utero fetal growth and development. They often persist postnatally, through childhood and adulthood. The purpose of this review is to discuss the prenatal factors that may have long term effects on postnatal weight gain and obesity that are important contributors to the “obesity” epidemic. These prenatal undesired factors are pregestational and gestational diabetes, pre-pregnancy maternal obesity, excessive weight gain in pregnancy, placental dysfunction and maternal hormonal imbalances. They may affect fetal growth, generally causing excessive growth (macrosomia) and sometimes diminished growth (small for gestational age). These prenatal conditions are associated with epigenetic changes that may contribute to insulin resistance and subsequent metabolic alterations leading to increased food intake, overweight, and obesity. Studies also demonstrate that increased exposure in pregnancy to teratogens, like endocrine disruptors and cigarette smoking, may also affect prenatal and postnatal growth and adiposity. However, many the studies demonstrating the role of these factors are often weakened, as they mainly demonstrate associations and do not sufficiently consider possible confounding factors such as postnatal age, nutrition and lifestyle. Better understanding of these prenatal factors may support more effective prevention and management strategies for childhood overweight and obesity.


  • Open Access

    Prenatal Origin of Childhood Overweight, Obesity and Insulin Resistance, with Special Emphasis on Maternal Diabetes, Excessive Weight, Nutrition and Hormone Imbalances

    by Asher Ornoy, Boniface Echefu, Maria Becker

    Overweight at childhood, adolescence and adulthood is now considered a world-wide epidemic. A variety of preventive and therapeutic measures are being developed with partial success. Since the pioneering studies of D.J. Barker linking maternal famine in pregnancy to long-term undesira-ble effects on the offspring, the "metabolic syndrome", that stems from long-lasting epigenetic changes, it became evident that there are many undesirable events which affect in utero fetal growth and development and persist postnatally, through childhood and adulthood. The purpose of this review is to discuss the prenatal factors that may have long term effects on postnatal weight gain and obesity that are major contributors to this epidemic of "overweight and obesity". Understanding these factors might help us find more effective preventive measures. The list of these prenatal undesired factors is connected to some maternal diseases that affect fetal growth: pregestational and gestational diabetes, p-pregnancy maternal overweight and obesity, excessive weight gain in pregnancy, placental dysfunction and maternal hormonal imbalances in pregnancy. They all affect fetal growth often causing excessive fetal growth (macro-somia) and sometimes diminished growth (small for gestational age). Due to long lasting epigenetic changes, they often lead to insulin re-sistance that induces metabolic alterations which may lead to increase in food intake, overweight and obesity. Studies also demonstrate that in-creased exposure in pregnancy to some teratogens, like endocrine dis-ruptors and cigarette smoking may affect fetal growth and adiposity, in-ducing epigenetic changes which lead to postnatal insulin resistance, overweight and obesity. Normalization of intrauterine fetal growth might open a new area of preventive measures for childhood obesity that might be more effective than the currently used dietary measures. In addition, early diagnosis of insulin resistance and proper treatment in addition to diet and exercises may be a more effective approach.


  • Open Access

    Methods for Assessing Neurodevelopmental Disorders in Mice: A Critical Review of Behavioral Tests and Methodological Considerations Searching to Improve Reliability

    by Boniface Echefu, Maria Becker, Dan Stein, Asher Ornoy

    Many neurobehavioral tests are used for the assessment of human-like behaviors in animals. Most of them were developed in rodents and are used for the assessment of animal models that mimic human neurodevelopmental and neuropsychiatric disorders (NDDs). We have described tests for assessing social behavior, social interaction, and social communication; tests for restricted and repetitive behaviors; tests for cognitive impairment, for sensory stimuli, for anxiety like behavior, and for motor coordination deviations. These tests are used to demonstrate autistic-like behavior as well as other NDDs. We described possible general pitfalls in the performance of such studies, as well as probable individual errors for each group of tests assessing specific behavior. The mentioned pitfalls may induce crucial errors in the interpretation of the results, minimizing the reliability of specific models of defined human NDD. It is imperative to minimize these pitfalls and use sufficient and reliable tests that can demonstrate as many of the traits of the human disorder, grade the severity of the specific deviations and the severity of the tested NDD by using a scoring system. Due to possible gender differences in the clinical presentations of NDD, it is important to carry out studies on males and females.


  • Open Access

    Methods for Assessing Neurodevelopmental Disorders in Rodents: A Critical Review of Behavioral Tests and Methodological Considerations Searching to Improve Reliability

    by Boniface Ezenwata Echefu, Maria Becker, Dan Stein, Asher Ornoy

    Many neurobehavioral tests are used for the assessment of human-like behaviors in animals. Most of them were developed in rodents and are used for the assessment of animal models that mimic human neurodevelopmental and neuropsychiatric disorders (NDD). We have described tests for assessing social behavior, social interaction and social communication; tests for restricted and repetitive behaviors; tests for cognitive impairment, for sensory stimuli, for anxiety like behavior and for motor coordination deviations. These tests are used to demonstrate autistic-like behavior as well as other NDD. We described possible general pitfalls in the performance of such studies, as well as probable individual errors for each group of tests assessing specific behavior. The mentioned pitfalls may induce crucial errors in the interpretation of the results, minimizing the reliability of specific models of defined human NDD. It is imperative to minimize these pitfalls and also use sufficient and reliable tests that are able to demonstrate as many of the traits of the human disorder, grade the severity of the specific deviations and the severity of the tested NDD by using a scoring system. Due to possible gender differences in the clinical presentations of NDD, it is important to carry out studies on males and females.


  • Open Access

    Animal Models of Autistic-like Behavior in Rodents: A Scoping Review and Call for a Comprehensive Scoring System

    by Asher Ornoy, Boniface Echefu, Maria Becker

    Appropriate animal models of human diseases are a cornerstone in the advancement of science and medicine. To create animal models of neuropsychiatric and neurobehavioral diseases such as autism spectrum disorder (ASD) necessitates the development of sufficient neurobehavioral measuring tools to translate human behavior to expected measurable behavioral features in animals. If possible, the severity of the symptoms should also be assessed. Indeed, at least in rodents, adequate neurobehavioral and neurological tests have been developed. Since ASD is characterized by a number of specific behavioral trends with significant severity, animal models of autistic-like behavior have to demonstrate the specific characteristic features, namely impaired social interactions, communication deficits, and restricted, repetitive behavioral patterns, with association to several additional impairments such as somatosensory, motor, and memory impairments. Thus, an appropriate model must show behavioral impairment of a minimal number of neurobehavioral characteristics using an adequate number of behavioral tests. The proper animal models enable the study of ASD-like-behavior from the etiologic, pathogenetic, and therapeutic aspects. From the etiologic aspects, models have been developed by the use of immunogenic substances like polyinosinic-polycytidylic acid (PolyIC), lipopolysaccharide (LPS), and propionic acid, or other well-documented immunogens or pathogens, like Mycobacterium tuberculosis. Another approach is the use of chemicals like valproic acid, polychlorinated biphenyls (PCBs), organophosphate pesticides like chlorpyrifos (CPF), and others. These substances were administered either prenatally, generally after the period of major organogenesis, or, especially in rodents, during early postnatal life. In addition, using modern genetic manipulation methods, genetic models have been created of almost all human genetic diseases that are manifested by autistic-like behavior (i.e., fragile X, Rett syndrome, SHANK gene mutation, neuroligin genes, and others). Ideally, we should not only evaluate the different behavioral modes affected by the ASD-like behavior, but also assess the severity of the behavioral deviations by an appropriate scoring system, as applied to humans. We therefore propose a scoring system for improved assessment of ASD-like behavior in animal models.